重症肌无力、NMOSD与MOGAD的生育规划与妊娠:现有证据与知识空白
本文综述重症肌无力、视神经脊髓炎谱系疾病(NMOSD)和髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)女性生育规划与妊娠期治疗证据。疾病加重或发作可发生于妊娠期且产后常见,可致可预防的长期残疾。许多药物标签保守,建议不必要的洗脱或避免哺乳。整合传统免疫抑制剂与生物制剂证据,提供治疗选择、婴儿疫苗接种及胎儿婴儿监测的专家建议。
要点
- 妊娠期可发生重症肌无力加重及NMOSD/MOGAD发作,产后常见。
- 部分新型疗法初步数据支持妊娠期继续使用以维持稳定且兼容哺乳。
- 提供治疗选择、婴儿疫苗接种及胎儿婴儿监测的专家建议。
核心结论
- 妊娠期疾病加重或发作及产后发作可导致可预防的长期母体残疾。
- 部分选定疗法初步数据支持妊娠期继续使用以维持疾病稳定且兼容哺乳。
研究设计与样本
- 个人观点(Personal View)文章,整合传统免疫抑制剂与生物制剂(含补体抑制、B细胞清除、新生儿Fc受体阻断)的现有证据。
主要发现
- 重症肌无力加重及NMOSD/MOGAD发作可发生于妊娠期,产后常见。
- 许多药物标签保守或建议不必要的延长洗脱或避免哺乳,给医患带来不确定性。
- 新型治疗妊娠安全性数据少,但初步数据提示部分选定疗法可妊娠期继续使用且兼容哺乳。
临床怎么用
- 为重症肌无力、NMOSD和MOGAD提供治疗选择、婴儿疫苗接种及胎儿婴儿监测的专家建议。
局限性
- 新型治疗妊娠安全性数据少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myasthenia gravis, neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are antibody-mediated neuroimmune disorders that frequently affect women in their reproductive years and require careful treatment planning around pregnancy. Disease exacerbations (for myasthenia gravis) and attacks (for NMOSD and MOGAD) can occur during pregnancy, are common postpartum, and can cause preventable, long-term maternal disability. Many drug labels are conservative or recommend unnecessary prolonged washouts or avoidance of breastfeeding, creating uncertainty for physicians and patients. This Personal View integrates available evidence on conventional immunosuppressants and biological therapies, including complement inhibition, B-cell depletion, and neonatal Fc receptor blockade. Although data on pregnancy safety for newer treatments are few, preliminary data suggest that selected therapies could be continued during pregnancy to maintain disease stability and are compatible with breastfeeding. We offer expert recommendations for therapy choice, infant vaccinations, and fetal and infant monitoring in myasthenia gravis, NMOSD, and MOGAD.
引用
- Rotstein DL, Alroughani R, Arrambide G, et al. Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD. Lancet Neurol. 2026. PMID: 41722595. doi:10.1016/S1474-4422(25)00479-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。